J.B Chemicals & Pharma announces DJSI score of 77

Published On 2025-03-09 05:00 GMT   |   Update On 2025-03-09 05:00 GMT

Mumbai: J.B. Chemicals & Pharmaceuticals Limited has announced that latest ESG score has been announced by Dow Jones Sustainability Index (DJSI), one of the world’s premier indexes in terms of sustainability.

J. B. Chemicals & Pharmaceuticals Limited’s DJSI score is 77, which will rank presently among the leading pharmaceutical companies in India and also rank among the leaders in Pharma Globally (Sector: DRG Pharmaceuticals, DJSI, S&P Global).

"This achievement underscores the Company’s steadfast commitment to sustainability, corporate responsibility, and environmental, social, and governance (ESG) excellence," JB Chemicals stated.

The DJSI ranking is a premier globally recognized benchmark for corporate sustainability, assessing companies with rigorous evaluation covering Environmental, Social and Governance and industry specific questionnaires, assessing an average of 23 sustainability topic through 150 questions/indicators, evaluating around 13,000 companies worldwide every year.

"JB Pharma’s score reflects its continuous efforts to integrate sustainable practices into its core business operations. Over the past year, JB Pharma has implemented several impactful sustainability initiatives, including renewable energy adoption, rainwater harvesting project, waste reduction programs, increased governance, community development projects etc. These efforts have not only contributed to a positive environmental and social footprint but have also strengthened the Company’s position as a leader in sustainable growth," it added.

"As JB Pharma continues its journey towards a more sustainable future, it remains committed to upholding the highest standards of corporate governance and responsible business practices, ensuring long-term value creation for all stakeholders," it further added.

J.B. Pharma was established in 1976. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has six brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also manufactures medicated lozenges. It has eightstate of the art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News